Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Biological Activity of Vesatolimod in HIV-1
NCT02858401Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vesatolimod in human immunodeficiency virus type 1 infection (HIV-1) (10 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and Any Treatment-Emergent Adverse Events (AEs) at Day 157 and Maximum Change From Baseline in Plasma Log10 HIV-1 RNA at Any Postdose Timepoint at Day 134. Started Jan 2015; status: completed.
02
Drugs
vesatolimod
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02858401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858401.